SILO PHARMA INC
SILONASDAQTrading Snapshot
- Day Range
- $3.71 – $3.82
- 52-Week Range
- $3.31 – $15.15
- Volume
- $2.11B
- Avg Volume
- $2.54B
- Shares Outstanding
- 1.3M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $72,120
- Last Q Revenue
- $18,496
- P/E Ratio
- —
- P/S Ratio
- 65.7x
- EPS (TTM)
- $-4.77
- Dividend Yield
- —
Why Investors Own SILO
- ✓High-growth profile — revenue up +28.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SILO PHARMA INC
A company profile for SILO PHARMA INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Silo Pharma Says EPO Grants Patent Covering Preventative Approach Of Lead Candidate SPC-15, Intranasal, Nose-To-Brain Treatment Targeting PTSD And Stress-Induced Affective Disorders
Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms developSARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
Silo Pharma’s QwikAgents Engages AWS Premier Tier Services Partner Caylent To Design And Build AWS-Native QwikAgents Platform
Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoptionSARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma
The trading volume of these stocks is deviating from the norm in today's session.
These stocks have an unusual volume in today's session
Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership
Silo Pharma's QwikAgents joins AMD's AI Developer Program, gaining cloud credits and tools to accelerate its AI agent platform.
Silo Pharma's QwikAgents Accepted Into Advanced Micro Devices' AMD AI Developer Program
Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced